New Report Finds Pipeline
Agents Aim to Address Unmet Needs of Advanced Patients in Limiting OFF Time
Most of the late-stage
pipeline agents are set to meet the needs of advanced patients, with five
agents expected to launch during the forecast period (Rytary, CVT-301,
opicapone, safinamide, and tozadenant); three of them will be used almost
exclusively in advanced patients (CVT-301, opicapone, tozadenant). Additional
launches of currently marketed drugs in specific markets will include Duodopa
in the US and Japan; Neupro in the US, Japan, and Brazil; Nouriast in the US,
5EU, and Japan; Apokyn in Japan; and Requip XL in Japan. GlobalData believes
that Newron's safinamide, Impax's Rytary for early and advanced patients and
Civitas' CVT-301 for advanced patients are most promising.
Newron and Zambon’s
dual-mechanism MAO-B and glutamate release inhibitor, safinamide, is expected
to be a strong competitor in the Parkinson's disease market for early and
advanced-stage Parkinson's disease patients, with forecast global sales of
$423.2m in 2022. Safinamide is likely to be prescribed over MAO-B inhibitor
Azilect (Teva/Lundbeck), due to novel activity as a glutamate release
inhibitor.
Impax's Rytary is a
slow-release formulation of levodopa that has shown good efficacy and
improvements in QOL during clinical trials. Impax is currently finalizing
regulatory issues and seeking a new partner for Rytary's ongoing clinical
development. In all, the pipeline candidate is forecast to generate sales of
$205.3m by 2022, following a late 2014 launch in the US.
Civitas' CVT-301 is a novel
reformulation of levodopa and the first inhaled device for Parkinson's disease.
It is expected to be the first widely used emergency therapy to meet a key unmet
need in wearing-off. Forecast to garner strong sales of $460.1m in 2022,
Civitas will likely require partnership for the marketing and sales of its
product.
UCB/Biotie's tozadenant is
expected to be the second-to-market A2A antagonist that will be used to treat
advanced patients, despite limited efficacy in Phase II trials. As a strong
player in the Parkinson's disease market, owing to UCB's longstanding presence
in the US market and extensive portfolio for Parkinson's disease, tozadenant is
forecast to generate global sales of $29.9m in 2022.
Know More About This “Global Drug Forecast and Market Analysis to 2022”
Report: http://mrr.cm/ZQd
Browse more than 25000 reports from our
pharma database - http://www.marketresearchreports.com/pharma-healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.